van der Meer J, Hillege H L, Ascoop C A, Dunselman P H, Mulder B J, van Ommen G V, Pfisterer M, van Gilst W H, Lie K I
Division of Haemostasis, Thrombosis and Rheology, University Hospital, Groningen, Netherlands.
Thromb Haemost. 1996 Jan;75(1):1-3.
To assess the thrombotic risk of aprotinin in aortocoronary bypass surgery, we retrospectively analyzed the results of a trial, originally designed to compare the effects of one-year treatment with various antithrombotic drugs in the prevention of vein-graft occlusion. Graft patency at one year was assessed by angiography. Myocardial infarction, thromboembolism, major bleeding, and death were clinical endpoints. Of 948 randomized patients, 42 received aprotinin, all enrolled by one of the participating centres. Occlusion rates of distal anastomoses were 20.5% in the aprotinin group and 12.7% in the non-aprotinin group (p = 0.091). The proportions of patients with occluded grafts were 44.1% versus 26.3% (p = 0.029). Perioperative myocardial infarction occurred in 14.3% and 7.0%, respectively (p = 0.12). Mean postoperative blood loss was 451 ml in the aprotinin group compared with 1039 ml in the non-aprotinin group (p < 0.0001). Mean transfusion requirements were 1.1 U versus 2.1 U of red blood cells (p = 0.004). Aprotinin decreases blood loss and transfusion requirement. Our data suggest that this benefit may be associated with a reduction of graft patency and an increased risk of myocardial infarction.
